Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Vasculo-Behcet's Disease: Profile and Management - Single Center Experience

Mohammed Abdullah Alsheef, MD, Kamal Gazal, MD, Nahar Alenizi, MD, Khalid Qushmaq, MD, Mukhtar Alomar, PharmD, Ghaydaa Juma Kullab, MD, Abdul Rehman Z. Zaidi, MBBS

Blood (2019) 134 (Supplement_1): 4955.

https://doi.org/10.1182/blood-2019-130548

Published: 2019

Journal Articles

Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials

Koung Jin Suh, Ji Yun Lee, Dong-Yeop Shin, MD PhD, Youngil Koh, MD PhD, Soo-Mee Bang, Sung-Soo Yoon, MD PhD, Seonyang Park, Inho Kim, Jeong-Ok Lee

Blood (2016) 128 (22): 1902.

https://doi.org/10.1182/blood.V128.22.1902.1902

Published: 2016

Journal Articles

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas CP Cross, MA, PhD, Andrzej Hellmann, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Almeida, MD PhD, Arpad Illes, MD PhD, Miguel Sagues, MD, Jens Haenig, PhD, Sharon Supekar, MSc, Seema Shah, MSc, Giuseppe Saglio, MD, Juan Luis Steegmann, MD, Michele Baccarani, MD

Blood (2016) 128 (22): 3094.

https://doi.org/10.1182/blood.V128.22.3094.3094

Published: 2016

Journal Articles

BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival

Jonathan Douxfils, Pharm.D PhDCandidate, Hélène Haguet, MSc, Christian J. Chatelain, MD, Carlos Graux, MDPhD, Jean-Michel Dogné, Pharm.D PhD

Blood (2015) 126 (23): 2785.

https://doi.org/10.1182/blood.V126.23.2785.2785

Published: 2015

Journal Articles

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas C.P. Cross, PhD, Andrzej Hellman, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Medina Almeida, Arpad Illes, MD PhD, Cristalina Fernandez, Luca Dezzani, Angela Pellegrino, Chiara Costantini, Claudia Walasek, Giuseppe Saglio, Juan Luis Steegmann, MD, Michele Baccarani

Blood (2015) 126 (23): 4040.

https://doi.org/10.1182/blood.V126.23.4040.4040

Published: 2015

Journal Articles

Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study

Ayala Gover-Proaktor, PhD, Oren Pasvolsky, MD, Pia Raanani, MD, Arnon Nagler, MD MSc, Saar Shapira, MSc, Ido Lubin, PhD, Galit Granot, PhD, Avi Leader, MD

Blood (2015) 126 (23): 2798.

https://doi.org/10.1182/blood.V126.23.2798.2798

Published: 2015

Journal Articles

High Prevalence of Peripheral Artery Occlusive Disease (PAOD) Among Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKIs): A Cross-Sectional Study

Thanawat Rattanathammethee, MD, Adisak Tantiworawit, MD, Ekarat Rattarittamrong, MD, Chatree Chai-Adisaksopha, MD, Sasinee Hantrakool, MD, Arintaya Phrommintikul, MD, Siriluck Gunaparn, RN, Lalita Norasetthada, MD

Blood (2015) 126 (23): 5140.

https://doi.org/10.1182/blood.V126.23.5140.5140

Published: 2015

Journal Articles

Lung Damage and Thrombocytopenia

Mo Yang, PhD, En Yu Liang, Li Xia Zhou, Beng H Chong, PhD, Chunfu Li, MD

Blood (2015) 126 (23): 4638.

https://doi.org/10.1182/blood.V126.23.4638.4638

Published: 2015

Journal Articles

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Hesam Hekmatjou, MD, Gail J. Roboz, MD, Ellen K. Ritchie, MD, Sangmin Lee, MD, Pinkal Desai, MD, Joseph M. Scandura, MD PhD, Sandra Allen-Bard, ANP, BS, BSN, MSN, NP, Paul Christos, DrPH, Richard T. Silver, MD, Eric J. Feldman, MD

Blood (2014) 124 (21): 1811.

https://doi.org/10.1182/blood.V124.21.1811.1811

Published: 2014

Journal Articles

Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib

Joanna Gora-Tybor, MD, PhD, Ewa Medras, MD, PhD, Malgorzata Calbecka, MD, PhD, Agnieszka Kolkowska, MD, Edyta Ponikowska-Szyba, MD, Tadeusz Robak, MD, PhD, Krzysztof Jamroziak, MD, PhD

Blood (2013) 122 (21): 1491.

https://doi.org/10.1182/blood.V122.21.1491.1491

Published: 2013

Journal Articles

Elevated Risk of Peripheral Artery Occlusive Disease (PAOD) in Nilotinib Treated Chronic Phase Chronic Myeloid Leukemia (CML) Patients Assessed by Ankle-Brachial-Index (ABI) and Duplex Ultrasonography

Michaela Schwarz, MD, Theo D. Kim, MD, Tristan Mirault, Peggy Grille, Delphine Rea, MD, PhD, Ruhdja Lindhorst, Herve Dombret, MD, Ivo Buschmann, Wilhelm Haverkamp, Bernd Doerken, Philipp le Coutre, MD

Blood (2012) 120 (21): 914.

https://doi.org/10.1182/blood.V120.21.914.914

Published: 2012

Journal Articles

Thrombotic Complications in Ph'-Negative Myeloproliferative Neoplasms - 10-Year Experience of A Medical Center in Asian Area

Yi-Sheng Chou, Ri-Dong Bai, Chung-Jen Teng, Ying-Chung Hong, Chun-Yu Liu, Yuan-Bin Yu, Liang-Tsai Hsiao, Jin-Hwang Liu, Hui-Chi Hsu, Tzeon-Jye Chiou, Po-Min Chen, Cheng-Hwai Tzeng, Jyh-Pyng Gau

Blood (2011) 118 (21): 5171.

https://doi.org/10.1182/blood.V118.21.5171.5171

Published: 2011

Journal Articles

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Michael J. Mauro, MD, Frank Hong, MD, PhD, MPH, Christine-Elke Ortmann, Richard C. Woodman, Philipp D. LeCoutre, MD, Giuseppe Saglio, MD

Blood (2011) 118 (21): 2757.

https://doi.org/10.1182/blood.V118.21.2757.2757

Published: 2011

Journal Articles

Depletion of Systemic Concentrations of Coagulation Factors in Blood From Patients with Atherosclerotic Vascular Disease

Kathleen E. Brummel-Ziedins, PhD, Philip Lam, M.D., Eric Gauthier, David Schneider, MD

Blood (2011) 118 (21): 1231.

https://doi.org/10.1182/blood.V118.21.1231.1231

Published: 2011

Journal Articles

Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?

Youngil Koh, Soo-Mee Bang, MD, PhD, Jae Hoon Lee, Hwi-Joong Yoon, Young-Rok Do, PhD, Hun-Mo Ryoo, Nari Lee, Seok Jin Kim, MD, PhD, Sung-Soo Yoon, MD, PhD, Jong-Ho Won, MD, PhD, Yeung-Chul Mun, MD, PhD, Moon-Hee Lee, Jong-Youl Jin, MD, PhD, Hyo-Jung Kim, HyeonSeok Eom, MD, PhD, Min Kyoung Kim, MD, Hyun Chun Shin, Korean Multiple Myeloma Working Party

Blood (2008) 112 (11): 5146.

https://doi.org/10.1182/blood.V112.11.5146.5146

Published: 2008

Journal Articles

Assessment of Plasma Prothrombotic Factors in Patients with Buerger’s Disease.

Iwona Hus, Bozena Sokolowska, Marek Chrapko, Aleksandra Nowaczynska, Adam Walter-Croneck, Kamila Mazurek, Magdalena Lewandowska, Jacek M. Rolinski, Anna Dmoszynska

Blood (2008) 112 (11): 2284.

https://doi.org/10.1182/blood.V112.11.2284.2284

Published: 2008

Journal Articles

Aldehyde Dehydrogenase-Activity Purifies Multiple Hemangiogenic Lineages That Accelerate Vascularization of Ischemic Tissue through Paracrine Support of Neovessel Formation.

Krysta D. Levac, PhD, Debra L. Robson, BSC, Marian J. Neelamkavil, BSc, Sarah A. Hohm, BSc, Benjamin J. Capoccia, BSc, Daniel C. Link, MD, Jan A. Nolta, PhD, David A. Hess, PhD

Blood (2007) 110 (11): 3716.

https://doi.org/10.1182/blood.V110.11.3716.3716

Published: 2007

Journal Articles

Lung Damage May Induce Thrombocytopenia.

Mo Yang, PhD, Da Wei Xiao, MD, Karen Kwai Har Li, PhD, Chi Kong Li, MD, Ki Wai Chik, MBBS, Tai Fai Fok, MD

Blood (2004) 104 (11): 3026.

https://doi.org/10.1182/blood.V104.11.3026.3026

Published: 2004

NARROW

Vasculo-Behcet's Disease: Profile and Management - Single Center Experience

Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study

High Prevalence of Peripheral Artery Occlusive Disease (PAOD) Among Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKIs): A Cross-Sectional Study

Lung Damage and Thrombocytopenia

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib

Elevated Risk of Peripheral Artery Occlusive Disease (PAOD) in Nilotinib Treated Chronic Phase Chronic Myeloid Leukemia (CML) Patients Assessed by Ankle-Brachial-Index (ABI) and Duplex Ultrasonography

Thrombotic Complications in Ph'-Negative Myeloproliferative Neoplasms - 10-Year Experience of A Medical Center in Asian Area

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Depletion of Systemic Concentrations of Coagulation Factors in Blood From Patients with Atherosclerotic Vascular Disease

Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?

Assessment of Plasma Prothrombotic Factors in Patients with Buerger’s Disease.

Aldehyde Dehydrogenase-Activity Purifies Multiple Hemangiogenic Lineages That Accelerate Vascularization of Ischemic Tissue through Paracrine Support of Neovessel Formation.

Lung Damage May Induce Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only